Skip to main content
. 2016 Oct 8;160(2):313–322. doi: 10.1007/s10549-016-4007-5

Fig. 2.

Fig. 2

PgR expression determined with IHC. Cumulative recurrence risk for patients with ER+/PgR+ tumors, HR = 0.43 (95 % CI 0.29–0.62), p < 0.001 (a) and ER+/PgR− tumors, HR = 0.87 (95 % CI 0.52–1.46), p = 0.59 (b). Cumulative breast cancer-specific mortality for patients with ER+/PgR+ tumors, HR = 0.44 (95 % CI 0.27–0.71), p = 0.001 (c) and ER+/PgR− tumors, HR = 0.65 (95 % CI 0.35–1.21), p = 0.17 (d)